Cite this answer
IGF-1 DES: quick citable summary
IGF-1 DES is listed by PeptaHub as a muscle & growth peptide with a research only legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “IGF-1 DES: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/igf-1-des. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/igf-1-des.
What is IGF-1 DES?
IGF-1 DES is a truncated IGF-1 missing three N-terminal amino acids. Reduced IGFBP binding leaves far more of it free to engage the IGF-1 receptor, and it is more potent than native IGF-1 in cultured cells and in GH-deficient mice. All published evidence is preclinical.
Overview
IGF-1 DES (Des(1-3)IGF-1) is a naturally occurring truncated form of insulin-like growth factor-1 in which the first three N-terminal amino acids (Gly-Pro-Glu) have been removed. This structural modification dramatically reduces binding affinity for IGF-binding proteins (IGFBPs), rendering significantly more circulating peptide bioavailable for receptor engagement. First isolated from human brain tissue, it is more potent than native IGF-1 in cultured cells, and that higher potency was confirmed in vivo in GH-deficient mice. Published sources do not support a single agreed potency multiplier, so none is quoted here.
Mechanism of action
IGF-1 DES activates the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase, with higher affinity than native IGF-1 because the N-terminal tripeptide normally facilitates IGFBP binding. Without IGFBP sequestration, virtually 100% of IGF-1 DES is free to engage IGF-1R. Receptor activation triggers auto-phosphorylation and downstream signaling through two primary cascades: (1) PI3K/Akt/mTOR, driving protein synthesis and inhibiting protein degradation via FoxO transcription factor suppression, and (2) MAPK/ERK, promoting cell proliferation. The very short half-life is the basis for the claim that effects stay near the injection site. The further claim that local injection drives satellite cell activation and new fibre formation rather than hypertrophy of existing fibres is widely repeated in the research-peptide market, but we could not locate a published study demonstrating it for des(1-3)IGF-I, so treat it as unsupported.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| localized muscle tissue research (preclinical) | subcutaneous | 20–100 mcg | once daily post-workout | Research protocols typically inject 20–100 mcg bilaterally into target muscle groups immediately post-exercise. Short half-life requires site-specific injection. Cycle 4–6 weeks. |
| localized muscle tissue research (preclinical) | intramuscular | 20–100 mcg | once daily post-workout | Direct intramuscular injection into target tissue is reported to maximize localized IGF-1R activation. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert IGF-1 DES research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? The IGF-1 DES dose calculator is preloaded with these ranges, or use the general dose unit converter.
Research summary
Gillespie et al. (J Endocrinol 1990) compared the two peptides in lit/lit GH-deficient mice. Daily injection of 30 µg of either peptide, or of just 3 µg of des(1-3)IGF-I, increased total and nose-rump length substantially versus controls, whereas 3 µg of IGF-I did not; body weight changes were not significant. The authors concluded that the higher potency previously seen in cultured cells also applies in vivo, but did not publish a potency multiplier. Other rat work found des(1-3)IGF-I anabolic after gut resection (Lemmey et al., Am J Physiol 1991) and in dexamethasone-treated animals (Tomas et al., Biochem J 1992). Yamamoto & Murphy (J Endocrinol 1995) showed IGF-I is enzymatically converted to des(1-3)IGF-I in rat serum and tissues. No controlled human clinical trials have been published, and none of the published literature we could retrieve demonstrates localized muscle hyperplasia in response to injected des(1-3)IGF-I. WADA prohibits it in competitive athletes.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with IGF-1 DES for synergistic effects.
Legal status
Not FDA-approved for any indication. Prohibited in sport by WADA. Available from research peptide suppliers in the US for laboratory use. Subject to import restrictions in some jurisdictions. Not a Schedule I–V controlled substance in the US but considered a prescription drug analogue in some countries.
Sourcing & access
Research compound
IGF-1 DES is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
IGF-1 DES (Des(1-3)IGF-1) is a truncated form of insulin-like growth factor-1 missing the first three amino acids. This modification sharply reduces binding to IGF-binding proteins, leaving much more of the peptide free to engage the IGF-1 receptor. It is more potent than native IGF-1 in cultured cells, and a mouse study confirmed that higher potency in vivo. Widely quoted multipliers of 2-3x or 10x do not trace to a specific published measurement.
Reduced IGFBP binding leaves far more of the peptide free to engage the IGF-1 receptor, triggering PI3K/Akt/mTOR (protein synthesis) and MAPK/ERK (cell proliferation) cascades. Its short 20-30 minute half-life is the reason effects are expected to stay near the injection site. The commonly claimed satellite-cell-driven hyperplasia is not supported by a published study we could find.
Side effects include dose-dependent hypoglycemia, injection site pain or swelling, jaw pain or facial growth with chronic high-dose use, organ hypertrophy risk with prolonged systemic exposure, and edema. It is WADA-prohibited and not FDA-approved for any indication.
IGF-1 DES has a very short half-life (20-30 minutes), so its effects are expected to be localized, while IGF-1 LR3 has a much longer half-life and broader systemic exposure. The often-stated contrast that DES uniquely drives site-specific muscle hyperplasia while LR3 produces generalized growth is not backed by published head-to-head data.
Research references
- Des(1-3)IGF-I: a truncated form of insulin-like growth factor-IReview
- Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit micePubMed
- IGF-I and the truncated analogue des-(1-3)IGF-I enhance growth in rats after gut resectionPubMed
- Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated ratsPubMed
- Enzymatic conversion of IGF-I to des(1-3)IGF-I in rat serum and tissues: a further potential site of growth hormone regulation of IGF-I actionPubMed